US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Binah Capital Group Inc

2.10

+0.02000.96%

Volume:3.84K

Turnover:8.06K

Market Cap:34.87M

PE:-17.90

High:2.10

Open:2.10

Low:2.10

Close:2.08

Loading ...

Overview Company News Filings

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer

Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025

Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

Press Release: Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting

Press Release: Binah Capital Group's David Shane Recognized Among Top 5 Wealth Management CFOs by Wealth Solutions Report

Stagwell (STGW) Unveils New SPORT BEACH 2025 Athletes and Brand Partners Including Erin Andrews, Sir Mo Farah, Chris Paul, Alex Rodriguez, George Russell, Charissa Thompson and More

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Press Release: BCG CEO Christoph Schweizer Reelected to a Second Term as Firm Achieves 10% Growth in 2024 and Record Revenue

Binah Capital Group Full Year 2024 Earnings: US$0.28 loss per share (vs US$0.43 profit in FY 2023)

Simply Wall St.

BRIEF-Binah Capital Group Reports Fourth Quarter And Full Year 2024 Results

Binah Capital Group Inc - Q4 2024 Revenue up 8% to $45 Million

THOMSON REUTERS

Binah Capital Group Inc - Aum Increased 13% to $27 Billion at Qtr-End

THOMSON REUTERS

Press Release: Binah Capital Group Reports Fourth Quarter and Full Year 2024 Results

CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates

Press Release: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BCG/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCG\",,,,,undefined,":{"symbol":"BCG","market":"US","secType":"STK","nameCN":"Binah Capital Group Inc","latestPrice":2.1,"timestamp":1750178277001,"preClose":2.08,"halted":0,"volume":3835,"delay":0,"floatShares":3144502,"shares":16602460,"eps":-0.117335,"marketStatus":"Trading","change":0.02,"latestTime":"06-17 12:49:57 EDT","open":2.1001,"high":2.1001,"low":2.1,"amount":8055.65527,"amplitude":0.000048,"askPrice":2.14,"askSize":315,"bidPrice":2.08,"bidSize":89,"shortable":3,"etf":0,"ttmEps":-0.117335,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1750190400000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":2.08,"postHourTrading":{"tag":"盘后","latestPrice":2.08,"preClose":2.08,"latestTime":"16:00 EDT","volume":8,"amount":16.64,"timestamp":1750104001186},"volumeRatio":0.712717},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCG\",,,,,undefined,":{"symbol":"BCG","floatShares":3144502,"roa":"-2.91%","roe":"-11.19%","lyrEps":-0.318929,"volumeRatio":0.712717,"shares":16602460,"dividePrice":0,"high":2.1001,"amplitude":0.000048,"preClose":2.08,"low":2.1,"week52Low":1.71,"pbRate":"90.32","psRate":"0.20","week52High":6.55,"institutionHeld":0,"latestPrice":2.1,"committee":-0.559406,"eps":-0.117335,"divideRate":0,"volume":3835,"delay":0,"ttmEps":-0.117335,"open":2.1001,"prevYearClose":2.94,"prevWeekClose":2.1,"prevMonthClose":2.22,"prevQuarterClose":1.93,"fiveDayClose":2.11,"twentyDayClose":2.49,"sixtyDayClose":2.14},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCG\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530171196","title":"CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2530171196","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530171196?lang=en_us&edition=fundamental","pubTime":"2025-04-27 04:10","pubTimestamp":1745698200,"startTime":"0","endTime":"0","summary":"- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C –。- 58.3% of patients showed durable complete responses by K-M at 24 months –。- 97.3% of all treated patients remained free from progression to MIBC at 24 months–。- 91.6% of responders remained cystectomy-free at 24 months –。- No Grade 3 or greater treatment-related adverse events or deaths reported –。- Strong initial Cohort P data reported 90.5% high-grade recurrence-free survival at 3 and 9 months by K-M –。- Company will host a conference call and webcast at 8 a.m. EDT on Monday, April 28, 2025 -. IRVINE, Calif., April 26, 2025  -- CG Oncology, Inc. , a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that cretostimogene grenadenorepvec monotherapy data was presented at the Practice-Changing, Paradigm-Shifting Clinical Trials in Urology Plen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cg-oncology-announces-best-disease-201000079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AFG","IE00B64PRP62.GBP","BK4107","US2Y.BOND","IE00BGHQF748.EUR","CG","US30Y.BOND","BK4585","BK4139","US6M.BOND","BK4588","CR","US3Y.BOND","BK4161","US12M.BOND","US5Y.BOND","BK4117","US7Y.BOND","BK4135","BCG","BOND","US10Y.BOND","CGON","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2530175941","title":"Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2530175941","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530175941?lang=en_us&edition=fundamental","pubTime":"2025-04-27 01:50","pubTimestamp":1745689800,"startTime":"0","endTime":"0","summary":"Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response  with more than half of responders remaining cancer-free at one year after CR. Results reinforce potential of TAR-200 to transform outcomes for certain types of BCG-unresponsive, high-risk non-muscle invasive bladder cancer. As of March 2025, 82.4 percent of the 85 enrolled patients in the study achieved a complete response  , meaning their cancer was undetectable following treatment. This high response rate translated into sustained disease control, with 52.9 percent of responders maintaining complete response at one year. The median duration of response  was 25.8 months , indicating that many patients remained cancer-free for over two years without the need for reinduction therapy. At 12 months, 86.6 perc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/johnson-johnsons-tar-200-monotherapy-175000318.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/johnson-johnsons-tar-200-monotherapy-175000318.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1244550577.SGD","LU1061106388.HKD","LU1066051811.HKD","LU2468319806.SGD","RC","LU0203347892.USD","JNJ","LU1221951046.USD","LU1059921491.USD","LU1674673691.USD","LU1032955483.USD","SG9999002232.USD","IE00B7SZLL34.SGD","IE00B1BXHZ80.USD","LU1023059063.AUD","LU1894683264.USD","BK4533","BK4504","LU2592432038.USD","LU1244550221.USD","IE00BDGV0183.EUR","OS","LU0234570918.USD","LU0114720955.EUR","BCG","LU0345769631.USD","CR","IE000M9KFDE8.USD","LU0345769128.USD","LU0912757837.SGD","LU2089984988.USD","LU0466842654.USD","IE00B19Z3B42.SGD","LU2129689431.USD","LU1244550494.USD","LU1074936037.SGD","LU2505996509.AUD","LU0792757196.USD","IE00BN8TJ469.HKD","LU1718418525.SGD","LU0795875086.SGD","IE00B2B36J28.USD","LU1929549753.HKD","IE00BLSP4239.USD","LU0882574055.USD","IE00BFTCPJ56.SGD","LU2430703178.SGD","LU2347655156.SGD","LU1914381329.SGD"],"gpt_icon":0},{"id":"2530175929","title":"Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2530175929","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530175929?lang=en_us&edition=fundamental","pubTime":"2025-04-27 01:30","pubTimestamp":1745688600,"startTime":"0","endTime":"0","summary":"Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of care  Bacillus Calmette-Guérin  regimen compared to SOC alone. Sasanlimab, a subcutaneously administered PD-1 inhibitor, in combination with BCG represents the first potential treatment advancement for BCG-nave, high-risk non-muscle invasive bladder cancer in more than 30 years. Results have been shared with global health authorities to support potential regulatory filings. \"New bladder cancer treatment options that help reduce rates of disease recurrence or progression are long overdue. Up to 50% of patients with high-risk non-muscle invasive bladder cancer may experience failure of BCG intravesical immunotherapy, yet it has been the standard of care after tumor resection for decades,\" said Neal Shore, M.D., FACS, Medical Director for START Carolina Research Center, and lead investigator ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-sasanlimab-combination-significantly-improves-173000786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4581","IE000M9KFDE8.USD","CR","IE0002270589.USD","SG9999002224.SGD","LU0225771236.USD","SG9999011175.SGD","SG9999013999.USD","LU0985481810.HKD","SOC","PFE","LU0170899867.USD","LU1883839398.USD","LU0289739699.SGD","SGXZ57979304.SGD","LU0321505439.SGD","BK4585","BCG","BK4007","BK4534","SG9999002232.USD","SG9999001176.USD","OS","BK4231","LU1059921491.USD","HR","BK4592","IE00BLSP4239.USD","BK4203","LU1894683348.USD","LU1057294990.SGD","BK4533","CI","LU1066053197.SGD","ADC","BK4213","IE00BSNM7G36.USD","LU0456855351.SGD","SG9999003800.SGD","BK4135","LU1023059063.AUD","BK4097","IE00BBT3K403.USD","LU0306806265.USD","BK4550","LU0234572021.USD","BK4588","LU0122379950.USD","LU1261432733.SGD"],"gpt_icon":1},{"id":"2529986685","title":"CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529986685","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529986685?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:00","pubTimestamp":1745496000,"startTime":"0","endTime":"0","summary":"IRVINE, Calif., April 24, 2025  -- CG Oncology, Inc. , a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 8:00 am ET on April 28, 2025, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer  to be presented on April 26, 2025, at a Plenary Session at the American Urological Association  Annual Meeting in Las Vegas, Nevada.About Bladder CancerMore than 85,000 people are estimated to be diagnosed with bladder cancer in 2025. NMIBC is the most common form of bladder cancer, representing approximately 75% of newly diagnosed cases. Bladder cancer is the sixth most common form of cancer in the United States, and men account for three quarters of newly diagnosed cases.Cretostimogene is an investigational, intravesical","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cg-oncology-host-conference-call-120000320.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["US2Y.BOND","US7Y.BOND","BK4218","US5Y.BOND","IE00B64PRP62.GBP","BK4181","CGON","US12M.BOND","IE00B3QW5Z07.USD","CG","US30Y.BOND","IE00BGHQF748.EUR","BK4139","BK4588","BK4585","BK4135","BCG","US3Y.BOND","US6M.BOND","US10Y.BOND","HST","BOND"],"gpt_icon":0},{"id":"2529502826","title":"Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529502826","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529502826?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:00","pubTimestamp":1745409600,"startTime":"0","endTime":"0","summary":"NEW YORK, April 23, 2025  -- Protara Therapeutics, Inc., a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Monday, April 28, 2025, to review updated safety and efficacy data from the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer , including data from patients who have reached the 12-month evaluation timepoint. The data will be featured during an interactive poster session at the American Urological Association 2025 Annual Meeting on Saturday, April 26, 2025, at 7:00 a.m. PT.TARA-002 is an investigational cell therapy in development for the treatment of NMIBC and of LMs, for which it has been granted Rare Pediatric Disease Designation by the U.S. Food and Drug Administration. TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/protara-therapeutics-host-conference-call-120000732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCG","BK4218","BK4139","BK4181","AEIS","HST","IE0031619046.USD","BK4588","IFN","IE00B66KJ199.SGD","BK4585","IE00B7SZL793.SGD","IE00B19Z4B17.USD","BK4135","BK4523","TARA","BK4157"],"gpt_icon":0},{"id":"2527042761","title":"Press Release: Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527042761","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527042761?lang=en_us&edition=fundamental","pubTime":"2025-04-16 04:13","pubTimestamp":1744747980,"startTime":"0","endTime":"0","summary":"NEW YORK, April 15, 2025  -- Protara Therapeutics, Inc. , a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer. Dr. Nicacio brings to Protara nearly 20 years of broad oncology, drug development, regulatory and commercial experience across leading biopharmaceutical and health technology companies.\"We are delighted to welcome Dr. Nicacio to the Protara team,\" said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. \"As a proven leader with deep expertise spanning all stages of drug development, his guidance and insight will be invaluable as we advance our therapeutic candidates for patients impacted by some of the most underserved cancers and rare diseases.\". Dr. Nicacio earned his Medical Degree from Faculdade de Ciencias Medicas de Minas Gerais and completed a molecular biology research fellowship at New York Blood Center. He is","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4135","TARA","LENZ","BCG","BK4007"],"gpt_icon":0},{"id":"2527413421","title":"ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2527413421","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527413421?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:00","pubTimestamp":1744718400,"startTime":"0","endTime":"0","summary":"Company to Provide Regulatory, Sales, and Platform Updates at Investor Day including:. In Q1, the company submitted a supplemental Biologics License Application  for use of ANKTIVA plus Bacillus Calmette-Guérin  in BCG-unresponsive non-muscle invasive bladder cancer  for the indication of papillary disease.In Q2, the company submitted to the U.S. Food and Drug Administration  an Expanded Access Protocol  for ANKTIVA for the treatment of lymphopenia as a BioShield against the adverse effects of chemotherapy, radiation and checkpoint inhibitors, following authorization of a Regenerative Medicine Advanced Therapy  designation for this indication in Q1.With a permanent J-code  awarded in January 2025, ImmunityBio’s Q1 2025 ANKTIVA unit sales volume grew 150% over unit sales volume in Q4 2024.CULVER CITY, Calif., April 15, 2025----ImmunityBio, Inc. , a leading immunotherapy company, today announced that it has completed multiple submissions to the FDA including an sBLA for BCG-unresponsive ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunitybio-announces-fda-submissions-supplemental-120000240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2360107671.USD","LU1791807156.HKD","BK4211","BK4139","BK4588","DFS","LU1668664300.SGD","IBRX","CARE","BCG","LU0106831901.USD","BK4166","LU1861217088.USD","BK4135","BK4585","LU1861220207.SGD"],"gpt_icon":0},{"id":"2526954081","title":"Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2526954081","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526954081?lang=en_us&edition=fundamental","pubTime":"2025-04-11 04:05","pubTimestamp":1744315500,"startTime":"0","endTime":"0","summary":"NEW YORK, April 10, 2025  -- Protara Therapeutics, Inc., a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announcedthat two presentations and a panel discussion highlighting the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer  will be featured at the upcoming American Urological Association  2025 Annual Meeting taking place fromApril 26, 2025to April 29, 2025 inLas Vegas.A copy of the abstract for the ADVANCED-2 interim analysis is now available on the AUA website. Updated safety and efficacy data, including data from patients who have reached the 12-month evaluation timepoint, will be featured during an interactive poster session on Saturday, April 26, 2025.ADVANCED-2  is a Phase 2 open-label trial assessing intravesical TARA-002 in NMIBC patients with carcinoma in situ or CIS  who are Bacillus Calmette-Guérin -unresponsive  and BCG-Nave . The BCG-Unresponsive c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/protara-therapeutics-present-interim-analysis-200500382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4523","BCG","BK4117","TARA","BK4135","IE0031619046.USD","BK4107","AFG","BK4157","IE00B66KJ199.SGD","IFN","AEIS","IE00B19Z4B17.USD","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2526483373","title":"Press Release: Binah Capital Group's David Shane Recognized Among Top 5 Wealth Management CFOs by Wealth Solutions Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2526483373","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526483373?lang=en_us&edition=fundamental","pubTime":"2025-04-10 04:00","pubTimestamp":1744228800,"startTime":"0","endTime":"0","summary":"NEW YORK, April 09, 2025  -- Binah Capital Group, Inc.  , a leading financial services enterprise that owns and operates a network of industry-leading firms empowering independent financial advisors, proudly announces that its Chief Financial Officer , David Shane, has been named one of the Top 5 Wealth Management CFOs by Wealth Solutions Report in their annual \"CFO 5\" list. This prestigious recognition highlights CFOs who have demonstrated exceptional leadership and strategic vision in the financial services industry.The full article detailing the \"CFO 5\" list is available on the Wealth Solutions Report website here.Binah Capital Group is a financial services enterprise that owns and operates a network of industry-leading firms that empower independent financial advisors. As a national broker-dealer aggregator, Binah specializes in delivering value through its innovative hybrid-friendly model, making it an optimal platform for RIAs navigating today's complex financial landscape. Binah","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCG","BK4135"],"gpt_icon":0},{"id":"2526646553","title":"Stagwell (STGW) Unveils New SPORT BEACH 2025 Athletes and Brand Partners Including Erin Andrews, Sir Mo Farah, Chris Paul, Alex Rodriguez, George Russell, Charissa Thompson and More","url":"https://stock-news.laohu8.com/highlight/detail?id=2526646553","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526646553?lang=en_us&edition=fundamental","pubTime":"2025-04-09 21:01","pubTimestamp":1744203660,"startTime":"0","endTime":"0","summary":"Registration now open for SPORT BEACH 2025 at sportbeach.com. NEW YORK, April 9, 2025 /PRNewswire/ -- Stagwell , the challenger network built to transform marketing, today launched registration for SPORT BEACH 2025 at sportbeach.com and announced an expanded lineup of athletes and brand partners.Notable new additions to this year's roster include sports broadcaster Erin Andrews, long-distance runner and Olympic Gold Medalist Sir Mo Farah, NBA legend Chris Paul, MLB All-Star Alex Rodriguez, and George Russell, Mercedes-AMG PETRONAS Formula One Team driver, who will participate in featured programming throughout the week.Back in its third year, SPORT BEACH will serve as the premiere destination for sport at the Cannes Lions International Festival of Creativity  from June 16-19, 2025.Chris Paul  - Chris Paul is a legendary NBA superstar, known for his competitive spirit an","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/stagwell-stgw-unveils-sport-beach-130100662.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/stagwell-stgw-unveils-sport-beach-130100662.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999015952.SGD","SG9999015945.SGD","LU1046421795.USD","LU1261432733.SGD","SG9999001424.SGD","BK4515","BK4532","LU0868494708.USD","IE00BMPRXR70.SGD","BK4573","IE00BSNM7G36.USD","SG9999015978.USD","BK4575","BK4585","BK4543","BK4598","IE00BGHQDM52.EUR","LU1169590202.USD","BK4605","BK4609","MMAT","STGW","LU0868494617.USD","BK4141","LU0079474960.USD","BK4561","DGE.UK","IE00BVYPNQ40.USD","LU0942090050.USD","BK4534","BK4512","BCG","BK4612","LU1119994496.HKD","LU1035775433.USD","LU1169589451.USD","BK4559","LU1917777945.USD","DEO","BK4527","BK4588","LU0348723411.USD","BK4009","LU0061475181.USD","LU1823568750.SGD","GB00BDT5M118.USD","LU1069344957.HKD","SG9999015986.USD"],"gpt_icon":1},{"id":"2524205095","title":"enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2524205095","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524205095?lang=en_us&edition=fundamental","pubTime":"2025-04-04 20:00","pubTimestamp":1743768000,"startTime":"0","endTime":"0","summary":"BOSTON & MONTREAL, April 04, 2025----enGene Holdings Inc. , a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to seven newly-hired employees, with a grant date of April 2, 2025. The inducement awards consist of a non-qualified stock options to purchase an aggregate 144,650 of the Company's common shares. The options each have an exercise price of $4.44 per share, which is equal to the closing price of the Company's common shares on April 2, 2025, the date of grant. Each stock option has a 10-year term and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the employee’s employment commencement date and the remainder vesting in equal amounts monthly for three years thereafter, subject to the employee’s continued service as an employee of, or other service provider to, the Company through the applicable vesting dates.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/engene-reports-inducement-grants-under-120000127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","NDAQ","ENGNW","ENGN","BK4588","LU2210149790.SGD","IE00BGHQF748.EUR","BK4139","BK4585","IE00BKPKM429.USD",".IXIC","BCG","IE00B64PRP62.GBP","BK4135","BK4112"],"gpt_icon":0},{"id":"2524411586","title":"Press Release: BCG CEO Christoph Schweizer Reelected to a Second Term as Firm Achieves 10% Growth in 2024 and Record Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2524411586","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524411586?lang=en_us&edition=fundamental","pubTime":"2025-04-03 01:01","pubTimestamp":1743613260,"startTime":"0","endTime":"0","summary":"BCG CEO Christoph Schweizer Reelected to a Second Term as Firm Achieves 10% Growth in 2024 and Record Revenue. BOSTON, April 2, 2025 /PRNewswire/ -- Boston Consulting Group  today announced the reelection of CEO Christoph Schweizer to a second four-year term, in a direct vote of BCG's more than 2,000 managing directors and partners.Since assuming the CEO role in 2021, Schweizer has driven BCG's growth, expanding BCG's consulting team every year. His second term begins on October 1, 2025.BCG is delivering major AI-driven transformation programs with some of the world's biggest companies, including L'Oréal, BMW, IBM and New York Life.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCG"],"gpt_icon":0},{"id":"2524980495","title":"Binah Capital Group Full Year 2024 Earnings: US$0.28 loss per share (vs US$0.43 profit in FY 2023)","url":"https://stock-news.laohu8.com/highlight/detail?id=2524980495","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524980495?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:59","pubTimestamp":1743595178,"startTime":"0","endTime":"0","summary":"This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.NasdaqGM:BCG Earnings and Revenue History April 2nd 2025. All figures shown in the chart above are for the trailing 12 month  period. Binah Capital Group shares are down 2.9% from a week ago.Don't forget that there may still be risks. For instance, we've identified   2 warning signs for Binah Capital Group   you should be aware of.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/binah-capital-group-full-2024-115938454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCGWW","BCG"],"gpt_icon":0},{"id":"2524061999","title":"BRIEF-Binah Capital Group Reports Fourth Quarter And Full Year 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2524061999","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524061999?lang=en_us&edition=fundamental","pubTime":"2025-04-01 06:39","pubTimestamp":1743460797,"startTime":"0","endTime":"0","summary":"BRIEF-Binah Capital Group Reports Fourth Quarter And Full Year 2024 ResultsMarch 31 (Reuters) - Binah Capital Group Inc BCG.O:BINAH CAPITAL GROUP REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTSBINAH","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUAB7RR1R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCG","BK4135"],"gpt_icon":0},{"id":"2524972899","title":"Binah Capital Group Inc - Q4 2024 Revenue up 8% to $45 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2524972899","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524972899?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:15","pubTimestamp":1743452100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUAB7RR1R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4135","BCG"],"gpt_icon":0},{"id":"2524697289","title":"Binah Capital Group Inc - Aum Increased 13% to $27 Billion at Qtr-End","url":"https://stock-news.laohu8.com/highlight/detail?id=2524697289","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524697289?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:15","pubTimestamp":1743452100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUAB7RR1R:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCG","BK4135"],"gpt_icon":0},{"id":"2524848972","title":"Press Release: Binah Capital Group Reports Fourth Quarter and Full Year 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2524848972","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524848972?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:15","pubTimestamp":1743452100,"startTime":"0","endTime":"0","summary":"- Grew Total Revenue 8% Year-over-Year to $45 Million in the Fourth Quarter 2024 -. - Assets Under Management  Increased 13% Year-over-Year to $27 Billion -. - GAAP Net Loss of $1.1 Million in the Fourth Quarter -. - Grew Adjusted EBITDA(*) 43% Year-Over-Year to $2.0 Million in the Fourth Quarter -. \"As we celebrate the one-year anniversary of our successful public listing, we're pleased to deliver our 2024 fourth quarter results,\" stated Craig Gould, Chief Executive Officer of Binah Capital Group. \"Beyond our solid financial performance, we've accomplished several key milestones over the past year: closing of the business combination, forming Binah Capital Group, Inc. and listing on the NASDAQ, successful recruiting efforts, significantly reducing our cost of funding through the successful refinancing of our senior credit facility at favorable terms, and maintaining a mature and stable business despite ongoing market volatility.\"","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCG","BK4135"],"gpt_icon":0},{"id":"2523456589","title":"CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2523456589","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523456589?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:00","pubTimestamp":1743422400,"startTime":"0","endTime":"0","summary":"- Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials in Urology - - Additional updates from across CG Oncol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052232/0/en/CG-Oncology-to-Participate-in-the-120th-American-Urological-Association-Annual-Meeting-with-a-Series-of-Key-Presentations-and-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AFG","CGON","IE00BGHQF748.EUR","BK4107","IE00B3QW5Z07.USD","BCG","BK4139","BK4135","BK4117","IE00B64PRP62.GBP","CG"],"gpt_icon":0},{"id":"2522430524","title":"Press Release: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522430524","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522430524?lang=en_us&edition=fundamental","pubTime":"2025-03-28 19:00","pubTimestamp":1743159600,"startTime":"0","endTime":"0","summary":"- Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin -Unresponsive Non-Muscle Invasive Bladder Cancer  -. - Initiated CORE-008 Clinical Trial of Cretostimogene Monotherapy in High-Risk BCG-Nave  and BCG-Exposed  NMIBC -. - Late-Breaking Clinical and First Translational Data from BOND-003 Cohort C Presented at the 40th Annual European Association of Urology Congress -. IRVINE, Calif., March 28, 2025  -- CG Oncology, Inc. , a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided business updates.Any Time in High-Risk  BCG-Unresponsive NMIBC with carcinoma in situ. reached but exceeds 28 months as of the data cutoff of Januar","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","IE00B64PRP62.GBP","LU0868494617.USD","LU1261432733.SGD","US2Y.BOND","IE00BGHQF748.EUR","CG","US30Y.BOND","LU1059921491.USD","IE00BSNM7G36.USD","HR","BK4585","CI","BK4139","US6M.BOND","BK4588","CR","BK4225","BK4203","US3Y.BOND","BK4161","LU0058720904.USD","US12M.BOND","US5Y.BOND","BK4196","US7Y.BOND","BK4135","IE00B19Z3B42.SGD","LU0289739699.SGD","BCG","US10Y.BOND","IE00B19Z3581.USD","CGON","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2521747112","title":"Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2521747112","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521747112?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:00","pubTimestamp":1742817600,"startTime":"0","endTime":"0","summary":"– Latest BOND-003 data show 75.5% of patients achieved a complete response at any time –– Median duration of response exceeds 28 months and is ongoing –– No close contact precautions needed post creto","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/24/3047782/0/en/Cretostimogene-Grenadenorepvec-Data-Continues-to-Demonstrate-Best-in-Class-Durability-of-Response-as-well-as-Consistent-and-Compelling-Safety-and-Efficacy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","CR","BK4161","BK4139","BCG","BK4135"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":102,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCG\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCG\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BCG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BCG","date":"2025-06-16","current":-17.897929,"percent":0.275,"low":-94.684933,"twenty":-19.247598,"median":-10.43842,"eighty":-7.496946,"high":216.897522,"avg":1.418705,"sd":56.703404,"marketCap":34865166},"quantilePoints":[{"date":"2024-04-12","current":47.846282,"twenty":47.314657,"median":50.799756,"eighty":52.276493,"marketCap":133339024},{"date":"2024-04-19","current":40.132439,"twenty":41.297957,"median":46.73873,"eighty":50.917895,"marketCap":111841925},{"date":"2024-04-26","current":203.935518,"twenty":44.420253,"median":50.799756,"eighty":187.977853,"marketCap":116447181},{"date":"2024-05-03","current":181.468046,"twenty":45.542573,"median":118.644354,"eighty":199.211588,"marketCap":103618254},{"date":"2024-05-10","current":158.424485,"twenty":47.403261,"median":158.424485,"eighty":194.026786,"marketCap":90460381},{"date":"2024-05-17","current":135.380923,"twenty":48.08256,"median":150.76106,"eighty":191.347973,"marketCap":77302507},{"date":"2024-05-24","current":216.897522,"twenty":50.268131,"median":142.815352,"eighty":191.347973,"marketCap":123848485},{"date":"2024-05-31","current":-70.098677,"twenty":46.96024,"median":139.70159,"eighty":188.726768,"marketCap":145945446},{"date":"2024-06-07","current":-77.180156,"twenty":40.710114,"median":130.655552,"eighty":184.646906,"marketCap":160689084},{"date":"2024-06-14","current":-52.991736,"twenty":-57.718026,"median":121.266741,"eighty":182.34255,"marketCap":110328794},{"date":"2024-06-21","current":-39.863152,"twenty":-52.943996,"median":66.796341,"eighty":180.865278,"marketCap":82995083},{"date":"2024-06-28","current":-46.865063,"twenty":-56.142596,"median":53.605557,"eighty":179.659743,"marketCap":97573062},{"date":"2024-07-05","current":-45.194153,"twenty":-52.896255,"median":49.470693,"eighty":176.203209,"marketCap":94094226},{"date":"2024-07-12","current":-42.966272,"twenty":-51.448132,"median":45.631177,"eighty":169.370177,"marketCap":89455779},{"date":"2024-07-15","current":-46.626362,"twenty":-50.795682,"median":45.409667,"eighty":167.641909,"marketCap":97076086},{"date":"2024-08-02","current":-31.986002,"twenty":-50.143231,"median":45.188156,"eighty":165.913642,"marketCap":66594857},{"date":"2024-08-09","current":-28.166778,"twenty":-49.363473,"median":40.613835,"eighty":159.576663,"marketCap":58643232},{"date":"2024-08-16","current":-20.272151,"twenty":-47.35838,"median":-24.029285,"eighty":158.424485,"marketCap":59802844},{"date":"2024-08-23","current":-19.247598,"twenty":-46.674102,"median":-19.602159,"eighty":156.120128,"marketCap":56780413},{"date":"2024-08-30","current":-19.866672,"twenty":-46.24444,"median":-19.585275,"eighty":147.891273,"marketCap":58606683},{"date":"2024-09-06","current":-18.302664,"twenty":-45.957998,"median":-19.585275,"eighty":144.080444,"marketCap":53992860},{"date":"2024-09-13","current":-15.251751,"twenty":-45.448768,"median":-19.106899,"eighty":140.947095,"marketCap":44992666},{"date":"2024-09-20","current":-16.883858,"twenty":-45.194153,"median":-18.403405,"eighty":138.834001,"marketCap":49807380},{"date":"2024-09-27","current":-18.009448,"twenty":-45.194153,"median":-18.156337,"eighty":136.530797,"marketCap":53127872},{"date":"2024-10-04","current":-14.801515,"twenty":-45.098673,"median":-18.009448,"eighty":129.710478,"marketCap":43664469},{"date":"2024-10-11","current":-15.139192,"twenty":-44.271652,"median":-17.794742,"eighty":123.304944,"marketCap":44660617},{"date":"2024-10-18","current":-13.732204,"twenty":-43.642912,"median":-16.883858,"eighty":121.209133,"marketCap":40510002},{"date":"2024-10-25","current":-11.706141,"twenty":-43.204974,"median":-16.377341,"eighty":95.05469,"marketCap":34533116},{"date":"2024-10-31","current":-12.147373,"twenty":-41.725024,"median":-16.067805,"eighty":68.991477,"marketCap":35834749},{"date":"2024-11-08","current":-12.325216,"twenty":-38.781038,"median":-15.870826,"eighty":54.048578,"marketCap":36359387},{"date":"2024-11-15","current":-19.641554,"twenty":-35.089122,"median":-15.983385,"eighty":51.154173,"marketCap":57942585},{"date":"2024-11-22","current":-9.482521,"twenty":-31.222157,"median":-15.814546,"eighty":49.736506,"marketCap":41174100},{"date":"2024-11-29","current":-9.867391,"twenty":-29.805862,"median":-15.758267,"eighty":48.08256,"marketCap":42834346},{"date":"2024-12-06","current":-9.217214,"twenty":-28.707835,"median":-15.561288,"eighty":47.403261,"marketCap":40011928},{"date":"2024-12-13","current":-11.205991,"twenty":-28.548701,"median":-15.251751,"eighty":45.542573,"marketCap":48645207},{"date":"2024-12-20","current":-8.873003,"twenty":-28.103124,"median":-15.039858,"eighty":44.420253,"marketCap":38517707},{"date":"2024-12-27","current":-11.66494,"twenty":-27.84851,"median":-14.773376,"eighty":41.348639,"marketCap":50637503},{"date":"2025-01-03","current":-10.555814,"twenty":-27.84851,"median":-14.407558,"eighty":41.145913,"marketCap":45822789},{"date":"2025-01-10","current":-10.364586,"twenty":-27.132405,"median":-13.712083,"eighty":40.517556,"marketCap":44992666},{"date":"2025-01-17","current":-9.599672,"twenty":-25.795677,"median":-13.338247,"eighty":11.509386,"marketCap":41672174},{"date":"2025-01-24","current":-9.561426,"twenty":-24.74539,"median":-12.325216,"eighty":-7.572649,"marketCap":41506150},{"date":"2025-01-31","current":-8.069843,"twenty":-22.526431,"median":-12.059139,"eighty":-7.572649,"marketCap":35031190},{"date":"2025-02-07","current":-8.299318,"twenty":-20.109959,"median":-11.84684,"eighty":-7.649141,"marketCap":36027338},{"date":"2025-02-14","current":-7.955106,"twenty":-19.799137,"median":-11.755302,"eighty":-7.809773,"marketCap":34533116},{"date":"2025-02-21","current":-7.534404,"twenty":-19.697834,"median":-11.685541,"eighty":-7.672088,"marketCap":32706846},{"date":"2025-02-28","current":-10.976517,"twenty":-19.697834,"median":-11.593582,"eighty":-7.542053,"marketCap":47649060},{"date":"2025-03-07","current":-8.567038,"twenty":-19.686578,"median":-11.300169,"eighty":-7.572649,"marketCap":37189510},{"date":"2025-03-14","current":-7.381421,"twenty":-19.641554,"median":-11.255905,"eighty":-7.572649,"marketCap":32042747},{"date":"2025-03-21","current":-7.151947,"twenty":-19.630298,"median":-11.225114,"eighty":-7.350824,"marketCap":31046600},{"date":"2025-03-28","current":-7.687386,"twenty":-19.585275,"median":-11.1295,"eighty":-7.412018,"marketCap":33370944},{"date":"2025-04-04","current":-7.242195,"twenty":-19.569517,"median":-10.842657,"eighty":-7.32062,"marketCap":33038895},{"date":"2025-04-11","current":-6.987445,"twenty":-19.454706,"median":-10.555814,"eighty":-7.159596,"marketCap":31876723},{"date":"2025-04-17","current":-7.496946,"twenty":-19.247598,"median":-10.43842,"eighty":-7.190192,"marketCap":34201067},{"date":"2025-04-25","current":-8.006447,"twenty":-18.9662,"median":-10.135111,"eighty":-7.242195,"marketCap":36525412},{"date":"2025-05-02","current":-8.388573,"twenty":-18.90992,"median":-9.982129,"eighty":-7.266684,"marketCap":38268670},{"date":"2025-05-09","current":-7.860875,"twenty":-18.572243,"median":-9.867391,"eighty":-7.314981,"marketCap":35861313},{"date":"2025-05-16","current":-8.406769,"twenty":-18.572243,"median":-9.867391,"eighty":-7.343175,"marketCap":38351682},{"date":"2025-05-23","current":-20.369548,"twenty":-19.247598,"median":-9.867391,"eighty":-7.381421,"marketCap":39679879},{"date":"2025-05-30","current":-18.835439,"twenty":-19.522241,"median":-9.943883,"eighty":-7.381421,"marketCap":36691436},{"date":"2025-06-06","current":-18.153613,"twenty":-19.522241,"median":-10.135111,"eighty":-7.442614,"marketCap":35363239},{"date":"2025-06-13","current":-17.471788,"twenty":-19.299375,"median":-10.401503,"eighty":-7.489139,"marketCap":34035043},{"date":"2025-06-16","current":-17.897929,"twenty":-19.247598,"median":-10.43842,"eighty":-7.496946,"marketCap":34865166}],"updateTime":1750158692041}}}